中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

11 records (took 0.021 seconds)

    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-PROMOTING AGENT
    2.
    发明专利
    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-PROMOTING AGENT 未知

    公开(公告)号：SG176728A1

    公开(公告)日：2012-01-30

    申请号：SG2011090750

    申请日：2010-06-08

    Applicant: ABBOTT LAB

    Inventor： SCHMITT ERIC A ,  TONG PING ,  HEEMSTRA KATHERINE ,  FISCHER CRISTINA M ,  WU HUAILIANG ,  MILLER JONATHAN MARK ,  LI YANXIA ,  LAFOUNTAINE JUSTIN S

    Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    Solid dispersions containing an apoptosis-promoting agent
    3.
    发明专利
    Solid dispersions containing an apoptosis-promoting agent 未知

    公开(公告)号：AU2010258943A1

    公开(公告)日：2012-01-19

    申请号：AU2010258943

    申请日：2010-06-08

    Applicant: ABBOTT LAB

    Inventor： SCHMITT ERIC A ,  TONG PING ,  HEEMSTRA KATHERINE ,  FISCHER CRISTINA M ,  WU HUAILIANG ,  MILLER JONATHAN MARK ,  LI YANXIA ,  LAFOUNTAINE JUSTIN S

    IPC: A61K9/00 ,  A61K9/14 ,  A61K31/5377 ,  A61K33/04 ,  A61P35/00

    Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-PROMOTING AGENT
    5.
    发明专利
    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-PROMOTING AGENT 未知

    公开(公告)号：CA2764103A1

    公开(公告)日：2010-12-16

    申请号：CA2764103

    申请日：2010-06-08

    Applicant: ABBOTT LAB

    Inventor： SCHMITT ERIC A ,  TONG PING ,  HEEMSTRA KATHERINE ,  FISCHER CRISTINA M ,  WU HUAILIANG ,  MILLER JONATHAN MARK ,  LI YANXIA ,  LAFOUNTAINE JUSTIN S

    IPC: A61K9/00 ,  A61K9/14 ,  A61K33/04 ,  A61P35/00

    Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    cápsula de abt-263
    6.
    发明专利
    cápsula de abt-263 未知

    公开(公告)号：BR112012014499A2

    公开(公告)日：2016-08-16

    申请号：BR112012014499

    申请日：2010-12-21

    Applicant: ABBOTT LAB

    Inventor： FISCHER CRISTINA M ,  ZHOU DELIANG ,  SCHMITT ERIC A ,  ZHANG GEOFF G Z ,  HEEMSTRA KATHERINE ,  CATRON NATHANIEL ,  TONG PING ,  SANZGIRI YESHWANT D

    IPC: A61K9/48 ,  A61K31/535 ,  A61K31/655

    Abstract: ''cápsula de abt-263'' uma cápsula farmacêutica compreende um invólucro de cápsula possuindo encapsulado em seu interior uma solução líquida de abt-263 ou um seu sal farmaceuticamente aceitável em um veículo substancialmente não etanólico que compreende como excipientes farmaceuticamente aceitáveis (a) pelo menos um fosfolípido, (b) pelo menos um agente solubilizante para o pelo menos um fosfolipídio, selecionado a partir do grupo que compreende glicóis, glicolídeos, glicerídeos e misturas desses, (c) pelo menos um tensoativo não-fosfolipídico e (d) pelo menos um antioxidante contendo enxofre. a cápsula é útil no tratamento de uma doença caracterizada pela superexpressão de uma ou mais proteínas antiapoptóticas da família bdl-2, por exemplo, o câncer.

    ABT-263 CAPSULE
    8.
    发明专利
    ABT-263 CAPSULE 未知

    公开(公告)号：SG181916A1

    公开(公告)日：2012-08-30

    申请号：SG2012046876

    申请日：2010-12-21

    Applicant: ABBOTT LAB

    Inventor： TONG PING ,  ZHOU DELIANG ,  ZHANG GEOFF G Z ,  HEEMSTRA KATHERINE ,  FISCHER CRISTINA M ,  CATRON NATHANIEL ,  SCHMITT ERIC A ,  SANZGIRI YESHWANT D

    Abstract: A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    ABT-263 capsule
    9.
    发明专利
    ABT-263 capsule 未知

    公开(公告)号：AU2010336518A1

    公开(公告)日：2012-06-07

    申请号：AU2010336518

    申请日：2010-12-21

    Applicant: ABBOTT LAB

    Inventor： TONG PING ,  ZHOU DELIANG ,  ZHANG GEOFF G Z ,  HEEMSTRA KATHERINE ,  FISCHER CRISTINA M ,  CATRON NATHANIEL ,  SCHMITT ERIC A ,  SANZGIRI YESHWANT D

    IPC: A61K9/48 ,  A61K31/535 ,  A61K31/655

    Abstract: A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    CAPSULA DE ABT-263.
    10.
    发明专利
    CAPSULA DE ABT-263. 未知

    公开(公告)号：MX2012007325A

    公开(公告)日：2012-07-20

    申请号：MX2012007325

    申请日：2010-12-21

    Applicant: ABBOTT LAB

    Inventor： TONG PING ,  HEEMSTRA KATHERINE ,  CATRON NATHANIEL ,  ZHOU DELIANG ,  SCHMITT ERIC A ,  FISCHER CRISTINA M ,  ZHANG GEOFF G Z ,  SANZGIRI YESHWANT D

    IPC: A61K9/48 ,  A61K31/535 ,  A61K31/655

    Abstract: Una cápsula farmacéutica comprende una caparazón que tiene encapsulado dentro del mismo una solución de líquido de ABT-263 o una sal farmacéuticamente aceptable del mismo en un vehículo substancialmente no etanólico que comprende como excipientes farmacéuticamente aceptables (a) por lo menos un fosfolípido, (b) al menos un agente de solubilización para dicho al menos un fosfolípido, seleccionado del grupo consistente de glicoles, glicéridos, y mezclas de los mismos, (c) al menos un tensioactivo que no es fosfolípido y (d) al menos un antioxidante que contiene azufre. La cápsula es útil en el tratamiento de una enfermedad caracterizada por la sobreexpresión de una o más proteínas antiapoptóticas de la familia Bcl-2, por ejemplo cáncer.

Patent Agency Ranking